Published in Neurobiol Dis on May 07, 2010
Comprehensive in vivo mapping of the human basal ganglia and thalamic connectome in individuals using 7T MRI. PLoS One (2012) 1.36
Limiting glutamate transmission in a Vglut2-expressing subpopulation of the subthalamic nucleus is sufficient to cause hyperlocomotion. Proc Natl Acad Sci U S A (2014) 1.04
Functional neuroanatomy of the basal ganglia. Cold Spring Harb Perspect Med (2012) 0.94
Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia. Front Neuroanat (2010) 0.88
Recent advances in the treatment of pain. F1000 Med Rep (2010) 0.86
Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network. Front Neurol (2014) 0.84
Are there three subdivisions in the primate subthalamic nucleus? Front Neuroanat (2012) 0.84
Past, present, and future of the pathophysiological model of the Basal Ganglia. Front Neuroanat (2011) 0.83
Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques. Front Neuroanat (2014) 0.83
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med (2013) 0.82
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct (2014) 0.81
Automatic target validation based on neuroscientific literature mining for tractography. Front Neuroanat (2015) 0.76
Basal Ganglia Circuits: What's Now and Next? Front Neuroanat (2012) 0.75
Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol (2014) 2.33
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol (2009) 2.28
Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov (2006) 2.23
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Coupling between beta and high-frequency activity in the human subthalamic nucleus may be a pathophysiological mechanism in Parkinson's disease. J Neurosci (2010) 1.81
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol (2009) 1.61
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. J Neurosci (2012) 1.43
Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of parkinsonism. J Neurochem (2013) 1.43
The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease. Mov Disord (2009) 1.41
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol (2006) 1.13
Expression of the mRNAs encoding for the vesicular glutamate transporters 1 and 2 in the rat thalamus. J Comp Neurol (2007) 1.11
Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J Comp Neurol (2004) 1.00
Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J Psychopharmacol (2010) 1.00
Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain (2011) 1.00
Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur J Neurosci (2005) 0.99
Reversible generalized dystonia and encephalopathy from thiamine transporter 2 deficiency. Mov Disord (2012) 0.97
LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation. Mov Disord (2011) 0.97
Thalamic innervation of the direct and indirect basal ganglia pathways in the rat: Ipsi- and contralateral projections. J Comp Neurol (2005) 0.97
Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem (2012) 0.96
Detection of two different mRNAs in a single section by dual in situ hybridization: a comparison between colorimetric and fluorescent detection. J Neurosci Methods (2007) 0.96
Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol (2004) 0.95
Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol Dis (2010) 0.94
Functional neuroanatomy of the basal ganglia. Cold Spring Harb Perspect Med (2012) 0.94
Aging of the rat mesostriatal system: differences between the nigrostriatal and the mesolimbic compartments. Exp Neurol (2006) 0.94
Glutamatergic pallidothalamic projections and their implications in the pathophysiology of Parkinson's disease. Neurobiol Dis (2008) 0.91
Expression of vesicular glutamate transporters 1 and 2 in the cells of origin of the rat thalamostriatal pathway. J Chem Neuroanat (2007) 0.91
Interleukin-6 and nitric oxide synthase expression in the vasopressin and corticotrophin-releasing factor systems of the rat hypothalamus. J Histochem Cytochem (2005) 0.89
Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat. Mov Disord (2004) 0.88
No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov Disord (2009) 0.88
Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol Dis (2009) 0.86
Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death. J Neuropathol Exp Neurol (2010) 0.85
Changes to interneuron-driven striatal microcircuits in a rat model of Parkinson's disease. Neurobiol Dis (2009) 0.85
Localization of relaxin-3 in brain of Macaca fascicularis: identification of a nucleus incertus in primate. J Comp Neurol (2009) 0.85
Beta activity in the subthalamic nucleus during sleep in patients with Parkinson's disease. Mov Disord (2009) 0.85
The significance of defining preclinical or prodromal Parkinson's disease. Mov Disord (2012) 0.84
Past, present, and future of the pathophysiological model of the Basal Ganglia. Front Neuroanat (2011) 0.83
Ischemia induces cell proliferation and neurogenesis in the gerbil hippocampus in response to neuronal death. Neurosci Res (2008) 0.81
Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration. Mov Disord (2013) 0.81
Glutamatergic and cholinergic pedunculopontine neurons innervate the thalamic parafascicular nucleus in rats: changes following experimental parkinsonism. Brain Struct Funct (2011) 0.81
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct (2014) 0.81
Electrophysiological and synaptic characterization of transplanted neurons in adult rat motor cortex. J Neurotrauma (2009) 0.80
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys. Mov Disord (2008) 0.80
Origin of calretinin-containing, vesicular glutamate transporter 2-coexpressing fiber terminals in the entorhinal cortex of the rat. J Comp Neurol (2008) 0.80
Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons. J Neurosci Res (2013) 0.79
Effects of dopaminergic cell degeneration on electrophysiological characteristics and GAD65/GAD67 expression in the substantia nigra: different action on GABA cell subpopulations. Mov Disord (2003) 0.79
Subthalamic activity during diphasic dyskinesias in Parkinson's disease. Mov Disord (2012) 0.79
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Mov Disord (2006) 0.79
The search for a role of the caudal intralaminar nuclei in the pathophysiology of Parkinson's disease. Brain Res Bull (2008) 0.79
Statistical parametric maps of ¹⁸F-FDG PET and 3-D autoradiography in the rat brain: a cross-validation study. Eur J Nucl Med Mol Imaging (2011) 0.79
High-resolution neuroanatomical tract-tracing for the analysis of striatal microcircuits. Brain Res (2008) 0.79
Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease. Front Syst Neurosci (2011) 0.78
Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys. Brain Struct Funct (2011) 0.78
G-protein-coupled receptor heteromers as key players in the molecular architecture of the central nervous system. CNS Neurosci Ther (2014) 0.78
'Functional' neuroanatomical tract tracing: analysis of changes in gene expression of brain circuits of interest. Brain Res (2006) 0.78
Modeling clinical features of neurodegeneration. Nat Med (2010) 0.77
The dopamine transporter is differentially regulated after dopaminergic lesion. Neurobiol Dis (2010) 0.77
The added value of rabies virus as a retrograde tracer when combined with dual anterograde tract-tracing. J Neurosci Methods (2010) 0.77
Striatal dopamine function in a family with multiple SCA-3 phenotypes. J Neurol (2010) 0.77
Unmasking adenosine 2A receptors (A2ARs) in monkey basal ganglia output neurons using cholera toxin subunit B (CTB). Neurobiol Dis (2012) 0.75
Scientific perspectives. Mov Disord (2014) 0.75
l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata. Synapse (2013) 0.75
Neuroanatomical tracing combined with in situ hybridization: analysis of gene expression patterns within brain circuits of interest. J Neurosci Methods (2009) 0.75
Proceedings of the workshop "Neuroanatomical Tracing and Systems Neuroscience: the State of the Art", 7th FENS meeting, Amsterdam, The Netherlands, July 3, 2010. J Neurosci Methods (2010) 0.75
Production of highly pure human glycosylated GDNF in a mammalian cell line. Int J Pharm (2009) 0.75
Movement disorders: improved understanding of early disease. Lancet Neurol (2013) 0.75